BCYC
Price
$2.90Alerts
Change
-$0.15 (-4.92%)
Updated
Nov 20 closing price
Capitalization
252.67M
101 days until earnings call
Intraday BUY SELL Signals
ZYME
Price
$26.14Alerts
Change
-$0.72 (-2.68%)
Updated
Nov 20 closing price
Capitalization
2.13B
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs ZYME

BCYC vs ZYME Comparison Chart in %
View a ticker or compare two or three
VS
BCYC vs. ZYME commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and ZYME is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCYC with price predictions
Nov 20, 2026

BCYC in downward trend: price dove below 50-day moving average on November 10, 2026

BCYC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend. In 43 of 48 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for BCYC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 185 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

BCYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 113 of 137 cases where BCYC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (3.596). P/E Ratio (-1.322) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (443.347).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ZYME with price predictions
Nov 20, 2026

ZYME in +3.95% Uptrend, rising for three consecutive days on November 19, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.

ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 186 of 221 cases where ZYME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 39 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In 68 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

ZYME moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.596). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (443.347).

The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
BCYC vs ZYME: Fundamental Ratings
BCYC
ZYME
OUTLOOK RATING
1..100
5937
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
7948
P/E GROWTH RATING
1..100
2978
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (36) in the null industry is somewhat better than the same rating for ZYME (83) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew somewhat faster than ZYME’s over the last 12 months.

ZYME's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that ZYME’s stock grew similarly to BCYC’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as ZYME (98) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as BCYC (79) in the null industry. This means that ZYME’s stock grew similarly to BCYC’s over the last 12 months.

BCYC's P/E Growth Rating (29) in the null industry is somewhat better than the same rating for ZYME (78) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew somewhat faster than ZYME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCZYME
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (BCYC: $2.90 vs. ZYME: $26.14)
Brand notoriety: BCYC and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 212% vs. ZYME: 105%
Market capitalization -- BCYC: $252.67M vs. ZYME: $2.13B
BCYC [@Biotechnology] is valued at $252.67M. ZYME’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green while ZYME’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than ZYME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 4 bearish.
  • ZYME’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than ZYME.

Price Growth

BCYC (@Biotechnology) experienced а -13.95% price change this week, while ZYME (@Biotechnology) price change was -0.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 02, 2027.

ZYME is expected to report earnings on Mar 10, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with PCVX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-4.92%
PCVX - BCYC
59%
Loosely correlated
-5.09%
EDIT - BCYC
56%
Loosely correlated
-4.09%
DYN - BCYC
55%
Loosely correlated
-3.31%
RCKT - BCYC
54%
Loosely correlated
-7.58%
RXRX - BCYC
54%
Loosely correlated
-9.93%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with REPL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-2.68%
REPL - ZYME
46%
Loosely correlated
-0.83%
DYN - ZYME
44%
Loosely correlated
-3.31%
BCYC - ZYME
40%
Loosely correlated
-4.92%
ENTA - ZYME
40%
Loosely correlated
-4.51%
VIR - ZYME
40%
Loosely correlated
-5.41%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SRS42.810.80
+1.90%
ProShares UltraShort Real Estate (SRS)
GJS23.350.06
+0.27%
Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group
AUGM34.85-0.05
-0.16%
FT Vest U.S. Equity Max Buffer ETF - August (AUGM)
QEFA94.84-1.64
-1.70%
State Street SPDR MSCI EAFE StrategicFactors ETF (QEFA)
WOOD61.27-1.25
-1.99%
iShares Global Timber & Forestry ETF (WOOD)